{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifts5qhl6vh6veoz2dh44plt345agine23hctpazs63lsjaxeawpq",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mf6opda22yq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidwtbmtnaaxz75wghoasytk5rknn24zqng4gdlgf23ugjgbtzhhze"
    },
    "mimeType": "image/jpeg",
    "size": 21711
  },
  "path": "/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants/",
  "publishedAt": "2026-02-18T21:03:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ — Prolacta Bioscience® today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone […]",
  "title": "A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants"
}